Lexicon Pharmaceuticals CEO Lonnel Coats, who departs July 7

Lex­i­con re­sub­mits type 1 di­a­betes drug to FDA five years af­ter re­jec­tion

Lex­i­con’s type 1 di­a­betes drug is fi­nal­ly get­ting an­oth­er shot at the FDA.

The biotech an­nounced Fri­day morn­ing that it had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.